In the first three months of this year, the total value of foreign licensing deals for innovative drugs in our country exceeded $60 billion.

2026-03-28 12:54:07

People’s Financial News, March 28 - A reporter learned today from the National Medical Products Administration that in the first three months of this year, the total value of foreign licensing transactions for innovative drugs in China exceeded $60 billion, approaching half of the total for the entire year of 2025. The latest statistics from the National Medical Products Administration show that as of March 27, 10 innovative drugs have been approved in China for 2026, including 2 imported and 8 domestically produced. China’s innovative drugs have achieved historic breakthroughs, maintaining a good development momentum and potential. (CCTV News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes